Long-lasting ovulation inhibition with a new injectable progestagen ORG-2154.
A new long-acting injectable progestagen was tested in 15 women who volunteered for the study. The occurrence of ovulation was assumed by the elevation of progesterone levels above 2ng/ml following a pre-ovulatory estradiol peak. Following a 200mg injection, ovulation was inhibited in all 15 women for five to ten months. In four subjects the interval between the injection and the first progesterone peak was five months. For eight, the interval was six to eight months. In the other three women, ovulation occurred more than eight months following injection. Bleeding episodes, similar to menstruation, occurred in most patients. Bleeding intervals lasting longer than 45 days occurred in nine subjects but more prolonged amenorrhea lasting longer than 60 days was reported by only five subjects. Blood chemistry which included blood cell counts, cholesterol, glucose, alkaline phosphatase, transaminases, urea nitrogen and creatinine remained within normal limits throughout the treatment.
D000328:Adult; D003271:Contraceptive Agents, Female; D004958:Estradiol / Q000097:blood; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D008598:Menstruation / Q000187:drug effects; D010060:Ovulation / Q000187:drug effects*; D011282:Pregnenediones / Q000494:pharmacology*; D011374:Progesterone / Q000097:blood
D003271:Contraceptive Agents, Female; D011282:Pregnenediones; D011374:Progesterone; D004958:Estradiol; C035491:16-alpha-ethyl-21-hydroxy-19-norpreg-4-ene-3,20-dione dodecanoate